Talquetamab Medicine 04 December 2025 Extended indication Talquetamab in combination with teclistamab and dexamethasone for second line or later treatment of Relapsed/refractory multiple myeloma in adults and elderly who have received an anti-CD38 antibody and lenalidomide. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Talquetamab Domain Hematology Reason of inclusion Indication extension IND Main indication Multiple Myeloma Extended indication Talquetamab in combination with teclistamab and dexamethasone for second line or later treatment of Relapsed/refractory multiple myeloma in adults and elderly who have received an anti-CD38 antibody and lenalidomide. Current proprietary name Already available biosimilars / generics Proprietary name Talvey Manufacturer Janssen Portfolio holder Janssen Mechanism of action Route of administration Subcutaneous Therapeutical formulation Concentrate for solution for injection / infusion Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Particularity ATMP No Submission date 2027 Expected Registration May 2027 Orphan drug Yes Registration phase Clinical trials Reimbursement Medicine sluice Broadly excluded Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT06208150 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks